We have previously shown that patients with early stage cervical cancer (IB/II) with PIK3CA exon 9 or 20 mutations treated with radical RT in combination with cisplatin had significantly worse outcome than those whose tumours expressed PIK3CA-WT [27]. The gene discussed is PIK3CA; the disease is cervical cancer.